Advertisement

Topics

Intrexon, Ziopharm and Merck KGaA Provide Update on the Development of their CAR-T Therapy

10:24 EDT 3 Apr 2017 | Speciality Pharma Journal

GERMANTOWN, Md. and BOSTON, April 03, 2017 (GLOBE NEWSWIRE) — Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ZIOPHARM Oncology (NASDAQ:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, today …

Original Article: Intrexon, Ziopharm and Merck KGaA Provide Update on the Development of their CAR-T Therapy

NEXT ARTICLE

More From BioPortfolio on "Intrexon, Ziopharm and Merck KGaA Provide Update on the Development of their CAR-T Therapy"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...